VS-041 / Vasa Therapeutics - LARVOL DELTA

Vasa Therapeutics Granted FDA Fast Track Designation for VS-041, a Novel Investigational Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF) (PRNewswire) - "'We are currently on track to have two assets in clinical development in 2026.'"

Fast track • Pipeline update • Heart Failure

A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) (clinicaltrials.gov) - P1 | N=42 | Recruiting | Sponsor: Vasa Therapeutics | Not yet recruiting ➔ Recruiting

Biomarker • Enrollment open • Cardiovascular • Congestive Heart Failure • Heart Failure

VS-041, a narrow-spectrum, matrix metalloproteinase (MMP) inhibitor and novel drug candidate for heart failure with preserved ejection fraction (HFpEF), demonstrates target engagement and is safe and well-tolerated in healthy participants. (AHA 2025) - "VS-041 is safe and well tolerated at doses that effectively inhibit key MMPs implicated in cardiac pathophysiology, offering promising therapeutic potential for patients with HFpEF."

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure • Inflammation • MMP9